Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
44 studies found for:    Tuberous Sclerosis
Show Display Options
Rank Status Study
21 Recruiting Tuberous Sclerosis Complex: Facial Angiofibroma Skin Cream
Condition: Facial Angiofibroma
Intervention: Drug: Rapamune
22 Recruiting Safety of Simvastatin in LAM and TSC
Conditions: Lymphangioleiomyomatosis;   Tuberous Sclerosis Complex
Intervention: Drug: Simvastatin
23 Terminated Studies of Autistic Patients: Gene Networks and Clinical Subtypes
Conditions: Autism;   Tuberous Sclerosis
Intervention:
24 Active, not recruiting Potential EEG Biomarkers and Antiepileptogenic Strategies for Epilepsy in TSC
Condition: Tuberous Sclerosis Complex
Intervention:
25 Active, not recruiting Topical Rapamycin to Erase Angiofibromas in TSC
Conditions: Angiofibromas;   Tuberous Sclerosis
Interventions: Drug: Placebo;   Drug: Rapamycin
26 Recruiting Rapalogues for Autism Phenotype in TSC: A Feasibility Study
Conditions: Tuberous Sclerosis Complex;   Self-injury;   Autism
Interventions: Drug: Sirolimus;   Drug: Everolimus
27 Completed Rapamycin In Angiomyolipomas In Patients With Tuberous Sclerosis
Condition: Angiomyolipoma
Intervention: Drug: Sirolimus
28 Unknown  Doxycycline In Lymphangioleiomyomatosis (LAM)
Conditions: Lymphangioleiomyomatosis;   Tuberous Sclerosis
Interventions: Drug: Doxycycline;   Drug: Placebo
29 Recruiting Study of the Disease Process of Lymphangioleiomyomatosis
Conditions: Lung Disease;   Pneumothorax;   Tuberous Sclerosis
Intervention:
30 Completed Effect of Fasting on the Size of Abdominal Lymphatic Tumors in Women
Conditions: Lymphangioleiomyomas;   Tuberous Sclerosis;   Lymphangioleiomyomatosis
Intervention:
31 Recruiting Everolimus for Cancer With TSC1 or TSC2 Mutation
Conditions: TSC1;   TSC2;   Tuberous Sclerosis Complex
Intervention: Drug: Everolimus
32 Recruiting Role of Genetic Factors in the Development of Lung Disease
Conditions: Cystic Fibrosis;   Sarcoidosis;   Tuberous Sclerosis;   Asthma
Intervention:
33 Recruiting Efficacy and Safety of Circadin® in the Treatment of Sleep Disturbances in Children With Neurodevelopment Disabilities
Condition: Sleep Disorders
Interventions: Drug: Circadin 2/5/10 mg;   Drug: Placebo
34 Completed Official Record of Patients Diagnosed With Lymphangioleiomyomatosis (LAM)
Condition: Leiomyomatosis
Intervention:
35 Withdrawn A Phase II Study of Orally Administered BEZ235 Monotherapy in Patients With Metastatic or Unresectable Malignant PEComa
Condition: Malignant PEComa (Perivascular Epithelioid Cell Tumors)
Intervention: Drug: BEZ235
36 Completed Assessment of the Pharmacokinetics of Circadin® in Children With Neurodevelopmental Disorders and Sleep Disturbances
Condition: Sleep Problems
Interventions: Drug: Circadin 2 mg;   Drug: Circadin 10 mg
37 Recruiting Long-term Follow-up for Growth and Development of Pediatric Patients From CRAD001M2301
Condition: Growth and Development
Interventions: Drug: Everolimus;   Drug: Envirolimus drug class as prescribed by Physician
38 Not yet recruiting Evaluation of New Biomarkers Predictive of Efficacy Betablockers in PEComa and Vascular Pediatric Tumors
Conditions: PEComa;   Hemangioma
Intervention: Other: Biopsy
39 Completed Arterial Spin Labeling MRI Focal Abnormalities in Refractory Epilepsy
Condition: Focal Epilepsy
Intervention: Device: Arterial spin labeled (ASL) MRI sequence
40 Recruiting Genetic Studies in Patients and Families With Infantile Spasms
Condition: Infantile Spasms
Intervention:

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-44) Show next page of results    Last Page
Indicates status has not been verified in more than two years